NCT06313970 2025-09-03
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Fudan University
Phase 2 Recruiting
Clinical Trials
23 trialsNCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT03351296 2024-05-08
BETTER2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Active not recruiting
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT06229340 2024-01-29
NТО-RAS
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Recruiting
NCT00114179 2020-10-30
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00602602 2020-04-27
Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00460174 2018-10-29
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
Northwestern University
Phase 2 Completed
NCT00557492 2018-09-25
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
University of Pittsburgh
Phase 2 Completed
NCT00365144 2018-01-19
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
University of California, San Francisco
Phase 2 Completed
NCT00366457 2017-05-15
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00609765 2017-03-23
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00112528 2016-12-13
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00100815 2015-12-24
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00417976 2015-10-01
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00253526 2015-04-28
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00305877 2014-05-21
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091026 2014-05-15
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00028834 2013-01-24
Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00126633 2012-09-17
Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
University of California, San Francisco
Phase 2 Completed
NCT00336648 2012-07-30
Preop Chemoradiation Resectable Pancreas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00326911 2011-05-25
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT00222469 2008-07-09
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
University of Oklahoma
Phase 2 Completed